Solid Biosciences Inc. (SLDB)

8.54 0.00 (0.00%) As of 11:06AM EDT. Market open.

Solid Biosciences Inc.

500 Rutherford Avenue
Third Floor
Charlestown, MA 02129
United States
617 337 4680
https://www.solidbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 88

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Ian F. Smith A.C.A., C.P.A.	Executive Chair	75k	N/A	1966
Mr. Alexander G. Cumbo	President, CEO & Director	1.82M	N/A	1971
Mr. Ilan Ganot	Co-founder, Strategic Advisor to the CEO & Director	1.36M	N/A	1974
Mr. David Tyronne Howton Jr., J.D.	COO & Secretary	1.4M	N/A	1972
Mr. Gilad David Hayeem	Co-Founder	N/A	N/A	1968
Ms. Annie Ganot	Co-Founder & Head of Patient Advocacy	N/A	N/A	N/A
Dr. Andrey Juan Zarur Ph.D.	Co-Founder	90.17k	N/A	1971
Mr. Kevin Tan C.F.A.	CFO & Treasurer	N/A	N/A	1977
Mr. Stephen J. Di Palma M.B.A.	Treasurer & Principal Accounting Officer	N/A	N/A	1959
Mr. Paul Herzich	Chief Technology Officer	N/A	N/A	1978

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Corporate Governance

Solid Biosciences Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.